Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carcinoma, Squamous Cell
ErbB Receptors
Erlotinib Hydrochloride
Female
Head and Neck Neoplasms
Humans
Male
Middle Aged
Multivariate Analysis
Quinazolines
Regression Analysis
Transforming Growth Factor alpha
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
authors with profiles
Kerstin M. Stenson
Elizabeth Blair
Mark Kozloff
Everett E. Vokes
Theodore Karrison
Ezra Cohen